|
1
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Costa C, Soares R and Schmitt F:
Angiogenesis: now and then. APMIS. 112:402–412. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klagsbrun M and Moses MA: Molecular
angiogenesis. Chem Biol. 6:R217–R224. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu J and Kapron CM: Differential
induction of MAP kinase signalling pathways by cadmium in primary
cultures of mouse embryo limb bud cells. Reprod Toxicol.
29:286–291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Page C and Doubell AF: Mitogen-activated
protein kinase (MAPK) in cardiac tissues. Mol Cell Biochem.
157:49–57. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoefen RJ and Berk BC: The role of MAP
kinases in endothelial activation. Vascul Pharmacol. 38:271–273.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tu Y: The development of new antimalarial
drugs: qinghaosu and dihydro-qinghaosu. Chin Med J (Engl).
112:976–977. 1999.
|
|
11
|
Crespo-Ortiz MP and Wei MQ: Antitumor
activity of artemisinin and its derivatives: from a well-known
antimalarial agent to a potential anticancer drug. J Biomed
Biotechnol. 2012:2475972012. View Article : Google Scholar
|
|
12
|
Chen HH, Zhou HJ, Wang WQ and Wu GD:
Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer
Chemother Pharmacol. 53:423–432. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Longo M, Zanoncelli S, Torre PD, et al: In
vivo and in vitro investigations of the effects of the antimalarial
drug dihydroartemisinin (DHA) on rat embryos. Reprod Toxicol.
22:797–810. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen HH, Zhou HJ and Fang X: Inhibition of
human cancer cell line growth and human umbilical vein endothelial
cell angiogenesis by artemisinin derivatives in vitro. Pharmacol
Res. 48:231–236. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu GD, Zhou HJ and Wu XH: Apoptosis of
human umbilical vein endothelial cells induced by artesunate.
Vascul Pharmacol. 41:205–212. 2004. View Article : Google Scholar
|
|
16
|
D’Alessandro S, Basilico N, Corbett Y, et
al: Hypoxia modulates the effect of dihydroartemisinin on
endothelial cells. Biochem Pharmacol. 82:476–484. 2011. View Article : Google Scholar
|
|
17
|
Sarina, Yagi Y, Nakano O, et al: Induction
of neurite outgrowth in PC12 cells by artemisinin through
activation of ERK and p38 MAPK signaling pathways. Brain Res.
1490:61–71. 2013. View Article : Google Scholar
|
|
18
|
Wang Y, Huang ZQ, Wang CQ, et al:
Artemisinin inhibits extracellular matrix metalloproteinase inducer
(EMMPRIN) and matrix metalloproteinase-9 expression via a protein
kinase Cδ/p38/extracellular signal-regulated kinase pathway in
phorbol myristate acetate-induced THP-1 macrophages. Clin Exp
Pharmacol Physiol. 38:11–18. 2011. View Article : Google Scholar
|
|
19
|
Lu JJ, Meng LH, Cai YJ, et al:
Dihydroartemisinin induces apoptosis in HL-60 leukemia cells
dependent of iron and p38 mitogen-activated protein kinase
activation but independent of reactive oxygen species. Cancer Biol
Ther. 7:1017–1023. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo L, Dong FY, Hou YL, et al:
Dihydroartemisinin inhibits VEGF-induced endothelial cell migration
by a p38 MAPK-independent pathway. Exp Ther Med. 8:1707–1712.
2014.PubMed/NCBI
|
|
21
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davis RJ: Transcriptional regulation by
MAP kinases. Mol Reprod Dev. 42:459–467. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Monick MM, Geist LJ, Stinski MF and
Hunninghake GW: The immediate early genes of human cytomegalovirus
upregulate expression of the cellular genes myc and fos. Am J
Respir Cell Mol Biol. 7:251–256. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dudley DT, Pang L, Decker SJ, Bridges AJ
and Saltiel AR: A synthetic inhibitor of the mitogen-activated
protein kinase cascade. Proc Natl Acad Sci USA. 92:7686–7689. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hong J, Kandasamy K, Marimuthu M, Choi CS
and Kim S: Electrical cell-substrate impedance sensing as a
non-invasive tool for cancer cell study. Analyst. 136:237–245.
2011. View Article : Google Scholar
|
|
26
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oh S, Jeong IH, Shin WS and Lee S: Growth
inhibition activity of thioacetal artemisinin derivatives against
human umbilical vein endothelial cells. Bioorg Med Chem Lett.
13:3665–3668. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feng D, Nagy JA, Pyne K, Hammel I, Dvorak
HF and Dvorak AM: Pathways of macromolecular extravasation across
microvascular endothelium in response to VPF/VEGF and other
vasoactive mediators. Microcirculation. 6:23–44. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boulton TG and Cobb MH: Identification of
multiple extracellular signal-regulated kinases (ERKs) with
antipeptide antibodies. Cell Regul. 2:357–371. 1991.PubMed/NCBI
|
|
30
|
García F, Zalba G, Páez G, Encío I and de
Miguel C: Molecular cloning and characterization of the human p44
mitogen-activated protein kinase gene. Genomics. 50:69–78. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Owaki H, Makar R, Boulton TG, Cobb MH and
Geppert TD: Extracellular signal-regulated kinases in T cells:
characterization of human ERK1 and ERK2 cDNAs. Biochem Biophys Res
Commun. 182:1416–1422. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He Y, Fan J, Lin H, et al: The
anti-malaria agent artesunate inhibits expression of vascular
endothelial growth factor and hypoxia-inducible factor-1α in human
rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int.
31:53–60. 2011. View Article : Google Scholar
|
|
33
|
Lee J, Zhou HJ and Wu XH:
Dihydroartemisinin downregulates vascular endothelial growth factor
expression and induces apoptosis in chronic myeloid leukemia K562
cells. Cancer Chemother Pharmacol. 57:213–220. 2006. View Article : Google Scholar
|
|
34
|
Yin D, Jia T, Gong W, et al: VEGF blockade
decelerates the growth of a murine experimental osteosarcoma. Int J
Oncol. 33:253–259. 2008.PubMed/NCBI
|
|
35
|
Kosaka C, Sasaguri T, Komiyama Y and
Takahashi H: All-trans retinoic acid inhibits vascular smooth
muscle cell proliferation targeting multiple genes for cyclins and
cyclin-dependent kinases. Hypertens Res. 24:579–588. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lu JJ, Meng LH, Shankavaram UT, et al:
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and
induces apoptosis in c-MYC-overexpressing tumor cells. Biochem
Pharmacol. 80:22–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lovren F, Pan Y, Quan A, et al: Adropin is
a novel regulator of endothelial function. Circulation. 122(Suppl
11): S185–S192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Alvarez G, Visitación Bartolomé M, Miana
M, et al: The effects of adiponectin and leptin on human
endothelial cell proliferation: a live-cell study. J Vasc Res.
49:111–122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Chen Q, Li G and Ke D: Ghrelin
stimulates angiogenesis via GHSR1a-dependent MEK/ERK and PI3K/Akt
signal pathways in rat cardiac microvascular endothelial cells.
Peptides. 33:92–100. 2012. View Article : Google Scholar
|
